| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,725 |
2,321 |
$213K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,323 |
2,779 |
$185K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
729 |
676 |
$98K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
846 |
787 |
$75K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
2,016 |
1,876 |
$73K |
| 99215 |
Prolong outpt/office vis |
631 |
585 |
$71K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,678 |
1,255 |
$35K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,408 |
2,290 |
$32K |
| 99205 |
Prolong outpt/office vis |
114 |
110 |
$19K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
189 |
165 |
$5K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,047 |
795 |
$3K |
| 81002 |
|
293 |
260 |
$804.94 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
13 |
12 |
$667.03 |
| 99051 |
|
54 |
49 |
$638.05 |
| 71046 |
Radiologic examination, chest; 2 views |
15 |
13 |
$370.68 |
| 81025 |
|
31 |
29 |
$201.60 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
30 |
25 |
$42.23 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
12 |
12 |
$12.54 |